Aminoglycoside Therapeutic Drug Monitoring: On Paper vs in Practice
- PMID: 37517034
- PMCID: PMC10724449
- DOI: 10.1093/cid/ciad446
Aminoglycoside Therapeutic Drug Monitoring: On Paper vs in Practice
Conflict of interest statement
Potential conflicts of interest. N. N. reports grants/contracts from Merck and Shionogi; consulting/speaker fees from Astellas, Beckman-Coulter, and Paratek; and an appointed role as an unpaid volunteer for the Clinical and Laboratory Standards Institute (CLSI; co-chair of the Breakpoint Working Group and Antimicrobial Susceptibility Testing (AST) Subcommittee advisor. J. S. L. reports consulting fees from Selux Diagnostics, Merck, Entasis, and La Jolla Pharmaceuticals and a role as chair of CLSI AST Subcommittee. Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
References
-
- Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America antimicrobial-resistant treatment guidance: gram-negative bacterial infections. Infect Dis Soc Am 2023; Version 3.0. Available at: https://www.idsociety.org/practice-guideline/amr-guidance/. Accessed 17 June 2023. - PubMed
-
- Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007; 60:247–57. - PubMed
-
- USCAST . The national antimicrobial susceptibility testing committee for the United States. Aminoglycoside in vitro susceptibility test interpretive criteria evaluations. Version 1.3, 2019. Available at: http://www.uscast.org. Accessed 25 June 2023.
-
- Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med 2019; 380:729–40. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
